Figure 4.

MUC1/CD3 BsAb can efficiently suppress MUC1-expressing tumors in B-NDG mice. (A) Schematic schedule of the in vivo study. Each B-NDG mouse was engrafted with 2.5 × 10⁶ HeLa cells in the right flank via subcutaneous injection on day −9. On day 0, the mice were randomized into three groups as indicated. For BsAb- and PBS (vehicle)-treated groups, each mouse was intraperitoneally injected with 1 × 10⁷ T cells. One hour later, the mouse was given 200 µL of a BsAb (250 µg/mL) solution or PBS via intraperitoneal injection, respectively. The PBS or antibody treatment was given twice per week for a total of 7 doses. Mice body weights and tumor sizes were measured twice per week. (B) Time course of tumor growth of different groups. (C) Tumor weight comparison between different groups. (D) Time course of body weight of different groups. Experimental data are presented as mean ± SEM (p < 0.05 (*)).